<DOC>
	<DOCNO>NCT00667927</DOCNO>
	<brief_summary>This study propose transfer marker gene ( detectable genetic trait segment DNA identify track ) aliquot marrow obtain Bone Marrow Transplant ( BTM ) patient remission Acute Myelogenous Leukemia ( AML ) .</brief_summary>
	<brief_title>Autologous Bone Marrow Transplant Children With Acute Myelogenous Leukemia ( AML ) First Complete Remission</brief_title>
	<detailed_description>The primary objective study estimate continuous complete remission rate 2 year post transplant child AML first complete remission treat autologous BMT . Secondary objective use transduction marker gene autologous marrow determine follow : 1. whether source relapse BMT AML residual malignant cell harvest marrow patient , whether marrow purge therefore rational . 2. whether majority AML , lack genetic marker , represent abnormality multi-lineage progenitor cell , whether therefore , auto grafting/intensified chemotherapy ever likely augment cure rate . 3. mechanism autologous reconstitution , effect stimuli modify process .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Patients age 1 18 year diagnosis acute nonlymphocytic leukemia first remission eligible protocol . Patients enrol AML87 study second subsequent remission eligible protocol . Has HLAmatched , MLCcompatible donor ( unless parent and/or patient refuse transplant . Diagnosis FAB M3 FAB M3v ( acute progranulocytic leukemia ) Life expectancy limit disease leukemia Significant cardiac disease ( echo shorten fraction &lt; 25 % MUGA scan &lt; 50 % ) Severe renal dysfunction , i.e. , creatinine clearance le 60cc/1.73 m2/min Severe restrictive pulmonary disease ( FCV less 40 % predict ) Severe hepatic disease ( bilirubin great 3 mg/dl SGPT great 500IU ) Severe personality disorder mental illness Previous severe cystitis cyclophosphamide Previous total dose anthracyclines &gt; 450 mg/m2 Sever infection evaluation PI preclude ablative chemotherapy successful transplantation Previous autologous transplant HIV reactivity Karnofsky score &lt; 70 %</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Autologous bone marrow transplant</keyword>
	<keyword>gene mark</keyword>
</DOC>